LUPIN

, India Rights Secured for Fortnightly GLP‑1 Candidate

has signed an exclusive licensing agreement with China-based Gan & Lee Pharmaceuticals to commercialise and distribute Bofanglutide in India, strengthening its presence in diabetes therapies and accelerating its entry into the obesity treatment space. Bofanglutide is a GLP‑1 injectable intended for Type 2 diabetes and weight management, with a key feature being less frequent administration once every two weeks compared with the weekly dosing common for current GLP‑1 therapies. Lupin also indicated the product could be “first-in-class” globally and cited clinical data suggesting weight-loss efficacy comparable to or better than existing GLP‑1 options, though specific trial metrics were not detailed in the article. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.